 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody technology platform, today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET 2:00 p.m. PT to discuss the results and provide a corporate update. 